Jinfang Zheng

机构：Hainan General Hospital, Hainan Medical University · ORCID：0000-0002-1098-8636

发表论文 27 篇 · 总被引 435 次 · h-index 8

代表论文

• Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study (2025 · The Lancet · 被引 292)
• Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial (2025 · The Lancet Oncology · 被引 49)
• 5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5’-deoxy-5-fluorouridine in patients with hepatocellular carcinoma (2005 · World Journal of Gastroenterology · 被引 17)
• Coagulation Dysfunction in Patients with Liver Cirrhosis and Splenomegaly and Its Countermeasures: A Retrospective Study of 1522 Patients (2023 · Disease Markers · 被引 14)
• LncRNA NORAD regulates the mechanism of the miR-532-3p/Nectin-4 axis in pancreatic cancer cell proliferation and angiogenesis (2023 · Toxicology Research · 被引 13)
• Circular RNA Fibroblast Growth Factor Receptor 1 Promotes Pancreatic Cancer Progression by Targeting MicroRNA-532-3p/PIK3CB Axis (2022 · Pancreas · 被引 12)